Key Insights

Highlights

Success Rate

89% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

4.3%

1 terminated out of 23 trials

Success Rate

88.9%

+2.3% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 8 completed with results

Key Signals

89% success

Data Visualizations

Phase Distribution

12Total
Not Applicable (9)
P 2 (3)

Trial Status

Completed8
Unknown4
Recruiting4
Not Yet Recruiting4
Enrolling By Invitation1
Terminated1

Trial Success Rate

88.9%

Benchmark: 86.6%

Based on 8 completed trials

Clinical Trials (23)

Showing 20 of 20 trials
NCT05425524Not ApplicableRecruitingPrimary

Leptospirosis Care Bundle Study

NCT07821853Phase 2CompletedPrimary

N-Acetylcysteine in Patients With Leptospirosis

NCT07808775Not Yet Recruiting

Assessment of the Risk of Zoonotic Infections in Prisons in French Guiana

NCT04034550Not ApplicableActive Not RecruitingPrimary

Cohort of Hospitalized Patients Suspected of Leptospirosis

NCT05436756Not ApplicableCompletedPrimary

Chronic Post-leptospirosis Manifestations in Reunion

NCT07611591Not Yet RecruitingPrimary

Ex Vivo Study of Leukocyte Responses in the Blood of Patients With Leptospirosis and ex Vivo Testing of a New Host-targeted Therapeutic Strategy to Restore Phagocytosis of Leptospira

NCT07127718Phase 2RecruitingPrimary

Preventive Strategies for Early and Late Complications of Leptospirosis

NCT07520279Enrolling By Invitation

Xpert® Tropical Fever Test on GeneXpert® Edge X System

NCT07358910Recruiting

Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective

NCT04288674RecruitingPrimary

Leptospirosis Registry - LeptoScope

NCT06945822Not ApplicableNot Yet RecruitingPrimary

Characterizing the Host Response to Leptospirosis for Better Diagnosis and Prognosis - NIHFI

NCT06859619Not ApplicableNot Yet Recruiting

Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases

NCT05300425CompletedPrimary

Seroprevalence of Leptospirosis in Val Müstair, Switzerland

NCT05413720Not ApplicableCompletedPrimary

Study of the Innate Immune Response to the Acute Phase of Human Leptospirosis - IMMUNOLEPTO

NCT04882046Not ApplicableUnknownPrimary

Study of the Incidence of Jarisch-Herxheimer Reaction in Leptospirosis Patients in New Caledonia

NCT02000635UnknownPrimary

Study of Decreasing Kinetics of the Leptospiremia During Antibiotic Treatment of Leptospirosis in Martinique

NCT03912506CompletedPrimary

Severe Leptospirosis in Non-tropical Areas

NCT03497572CompletedPrimary

Seroprevalence Study to Evaluate the Persistence of Anti-leptospira Antibody in Subjects Vaccinated With Spirolept® Vaccine

NCT01607047UnknownPrimary

French West Indies Leptospirosis Study

NCT01080989Not ApplicableCompleted

The Sero-Prevalence and Genetic Study for the Infectious Diseases and Metabolic Syndrome in Solomon Islands

Scroll to load more

Research Network

Activity Timeline